Cases & Deals

  • Home
  • Practices
  • Shanghai Zhenge Biotech raises $51 million in Series A round

Share

Shanghai Zhenge Biotech raises $51 million in Series A round

March 2020

Client(s) Shanghai Zhenge Biotech Co., Ltd.

Jones Day represented Shanghai Zhenge Biotech Co., Ltd., a Shanghai-based CDMO (“Contract Development and Manufacturing Organization”) company for biotech companies developing antibodies and other protein drugs, in connection with the $51 million Series A round of financing led by LYFE Capital.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.